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Prognostic Value of Elevated Levels of 
Intestinal Microbe-Generated Metabolite 
Trimethylamine-N-Oxide in Patients 
With Heart Failure
Reﬁning the Gut Hypothesis
W.H. Wilson Tang, MD, Zeneng Wang, PHD, Yiying Fan, PHD, Bruce Levison, PHD, Jennie E. Hazen, 
Lillian M. Donahue, Yuping Wu, PHD, Stanley L. Hazen, MD, PHD
T here is increasing recognition that the gastro-intestinal system represents an often over-looked contributor to the pathogenesis of
heart failure (HF) syndrome and its adverse complica-
tions (1,2). Normally, intestinal barrier function
is maintained by a well-balanced intestinal microbial
community, intact tight junctions in the mucosa,
normal mucosal immunity, and normal sodium
and water homeostasis. With HF and associated
splanchnic circulation congestion, bacterial translo-
cation can occur due to altered intestinal barrier func-
tion, bacterial overgrowth, and impaired host
defense, leading to endotoxemia that in turn can
contribute to systemic inﬂammation. Several of these
features of altered intestinal function have been
observed in patients with HF (3,4). Meanwhile, pro-
gressive venous congestion in subsets of patients
with signiﬁcant congestive signs and symptoms may
lead to unwanted consequences of abdominal conges-
tion, including adverse impact on drug absorption
and pharmacokinetics (5,6), and renal glomerular
and tubular dysfunction resulting from raised intra-
abdominal pressures (7,8).
Intestinal microbiota are implicated in the re-
gulation of multiple host metabolic pathways that
contribute to phenotypes such as obesity and in-
sulin resistance (9). Our group has recently described
a mechanistic link between intestinal microbe-
dependent generation of trimethylamine-N-oxide
(TMAO) and increased risk for future cardiovascular
events (death, myocardial infarction, and stroke)
by a pathway involving dietary nutrients such as
phosphatidylcholine, choline, and carnitine (10–12).
In chronic systolic HF, the relationship between
the intestinal microbiota-generated metabolite TMAO
and both cardiorenal indexes and long-term clinical
prognosis has not been examined. We sought to
investigate the relationship between fasting plasma
TMAO levels and long-term clinical prognosis in pa-
tients with stable HF undergoing cardiac evaluation,
particularly in relation with established prognostic
markers (B-type natriuretic peptide [BNP] and esti-
mated glomerular ﬁltration rate [eGFR]).
METHODS
STUDY POPULATION. We prospectively enrolled pa-
tients with stable cardiac disease seen at the Cleve-
land Clinic between 2001 and 2007 with a history of
HF undergoing elective, nonurgent coronary angio-
graphic evaluation. We excluded those patients who
had experienced acute coronary syndrome within the
preceding 30 days (cardiac troponin I #0.03
ng/ml). All-cause mortality was prospectively
tracked for 5 years with the Social Security
Death Index and medical chart review and
conﬁrmed by follow-up contact. We also
performed a cross-sectional comparison of
TMAO levels between our cohort of patients
with stable systolic HF and an independent
set of 300 prospectively recruited, apparently
healthy subjects without known cardiac dis-
ease from a health-screening program at
various locations across Cleveland, Ohio.
All subjects for all studies gave written
informed consent approved by the Cleveland
Clinic Institutional Review Board.
STUDY DESIGN AND ASSAY MEASUREMENTS. This
is a single-center, prospective cohort study approved
by the Cleveland Clinic Institutional Review Board.
After informed consent was obtained from all pa-
tients, fasting plasma blood samples were collected
using EDTA tubes, which were then immediately
processed and frozen at 80C until analysis. Fasting
plasma TMAO levels were quantiﬁed by stable isotope
dilution liquid chromatography with online tandem
mass spectrometry (LC/MS/MS) on an APi 500 triple
quadruple mass spectrometer (AB SCIEX, Framing-
ham, Massachusetts), as previously described (10–12).
BNP, high-sensitivity C-reactive protein (hsCRP),
fasting lipid panel, uric acid, and serum creatinine
were measured using the Architect ci8200 platform
(Abbott Laboratories, Abbott Park, Illinois). Serum
arylesterase activity was measured in the same plat-
form as previously described (13).
STATISTICAL ANALYSES. Continuous variables are
summarized as mean  SD if normally distributed and
median (interquartile range [IQR]) if not normally
distributed. The Student t test or Wilcoxon-rank
sum test for continuous variables and chi-square
test for categorical variables were employed to ex-
amine between-group differences. Spearman corre-
lation was used to examine the associations between
TMAO and other laboratory measurements. Kaplan-
Meier survival plots and Cox proportional hazards
analysis were used to determine hazard ratio (HR)
and 95% CI for all-cause mortality stratiﬁed according
to TMAO as a continuous variable (log-transformed
per SD increase), as well as according to quartiles.
Adjustments were made for individual traditional
risk factors, including age, sex, systolic blood pres-
sure, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol (HDL-C), smoking,
diabetes mellitus, and BNP, to predict all-cause mor-
tality risks. Net reclassiﬁcation and area under the
AB BR E V I A T I ON S
AND ACRONYM S
BNP = B-type natriuretic
peptide
eGFR = estimated glomerular
ﬁltration rate
HDL-C = high-density
lipoprotein cholesterol
HF = heart failure
hsCRP = high-sensitivity
C-reactive protein
TMAO = trimethylamine-
N-oxide

inverse correlation between TMAO levels and eGFR
(r 0.55; p < 0.001) in our study cohort. We further
investigated the association between TMAO levels
and cardiorenal indexes by constructing a model that
included BNP levels and eGFR. In this model, patients
in the highest quartile of TMAO (>8.5 mM) remained
at a signiﬁcantly higher mortality risk than those
with lower TMAO levels. Speciﬁcally, elevated fasting
TMAO levels were associated with a 2.2-fold increase
in mortality risk after adjustment for traditional risk
factors and BNP levels (HR: 2.20; 95% CI: 1.42 to 3.43;
p < 0.01) and a 1.80-fold increase in mortality risk
even after adjustment for traditional risk factors
and BNP levels plus eGFR (HR: 1.75; 95% CI: 1.07 to
2.86; p < 0.05) and plus hsCRP levels (HR: 1.85; 95%
CI: 1.14 to 3.00; p < 0.05). Interestingly, within
the intermediate BNP range (second tertile 160 to
505 pg/ml), the lower 2 tertiles of TMAO portended a
3.3-fold increase in mortality risk (95% CI: 1.4 to 8;
p < 0.001), whereas the highest TMAO tertile (>7.2
mM) had a 5.7-fold increased mortality risk (95% CI:
2.5 to 13.2; p < 0.01) compared with both low BNP
and TMAO levels (Figure 3).
DISCUSSION
The key ﬁnding to our study is the strong prognostic
value of plasma TMAO levels in patients with stable
HF incremental to traditional risk factors, cardiorenal
indexes (BNP and eGFR), and markers of systemic
inﬂammation (hsCRP). It is intriguing that in the
setting of elevated natriuretic peptide levels, which
often represent signiﬁcant myocardial disease pro-
gression, a relatively low fasting TMAO level was
associated with far lower mortality risk than that seen
with elevated levels of both markers. These observa-
tions in a large population of HF patients further
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CENTRAL ILLUSTRATION Comparison of Fasting TMAO Levels Between Patients With Stable Heart Failure and
Apparently Healthy Controls
(Left) Trimethylamine N oxide (TMAO) concentration was higher in patients with stable heart failure than healthy controls and (Right)
portended poorer survival at higher levels regardless of B type natriuretic peptide levels. Kaplan Meier curves for 5 year all cause mortality
with TMAO with TMAO/B type natriuretic peptide (BNP) stratiﬁed at median levels.
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FIGURE 1 Kaplan-Meier Estimates of Risk of All-Cause
Mortality According to Quartiles of Plasma Levels of TMAO
Kaplan Meier curves for 5 year all cause mortality with
trimethylamine N oxide (TMAO) stratiﬁed as quartiles.
reﬁne the notion of a “gut hypothesis” and suggest
a potential association between the gut microbiota
pathway of known proatherogenic potential with
adverse prognosis in patients with HF.
Although TMAO has been shown to possess proa-
therogenic properties (10–12), which might partially
contribute to the adverse prognosis associated with
higher TMAO levels, the equivalent adverse prog-
nostic value of elevated TMAO levels in both ische-
mic and nonischemic HF suggests the possibility
that other potential mechanisms contribute to the
increased mortality risks observed in patients with
HF with elevated TMAO levels. Our recent identiﬁ-
cation of the host-microbiome relationship in forma-
tion of TMAO (10–12) has generated novel insights
into potential contributions of environmental factors
within the traditional deﬁnition of “self.” Although
the “gut hypothesis” in HF has prevailed over the
years, with evidence implying bacterial translocation
and heightened inﬂammatory responses and oxida-
tive stress, few studies have deﬁnitively linked
such associations with outcomes or directly demon-
strated such processes at the bedside. Our current
observations therefore provided direct evidence
that accumulation in the systemic circulation of
TMAO, an obligatory downstream metabolite of gut
microbiota, heralds increased long-term adverse
clinical outcomes in patients with HF independently
of multiple cardiorenal indexes. It remains to be
determined whether elevated TMAO levels are
associated with enhanced gut edema and bacterial
translocation in HF; we have not identiﬁed an
alteration in the microbial composition within pa-
tients with HF at increased adverse prognosis as
the source of elevated TMAO levels among those
at increased mortality risk. In the setting of HF,
where ischemic or atherogenic processes appear less
important in long-term prognosis and progression,
the underlying mechanisms for the association be-
tween TMAO and adverse outcomes are not entirely
understood.
Clearly, other factors such as individual variations
in gut microbiota composition and impaired renal
clearance may inﬂuence systemic TMAO levels. The
notion that alterations in microbial composition and
gut microbial functional physiology may be part
of the HF syndrome is attractive (2). Changes in
bacterial composition have been shown to serve as
a primary driver of TMAO levels in other studies
(10,15). Whether microbial composition changes in
HF directly or indirectly contribute to enhanced
oxidative stress and inﬂammation is unclear, but we
did note that plasma TMAO levels were modestly
yet positively correlated with serum uric acid levels
and inversely correlated with PON1 activity as
monitored by serum arylesterase activity. Impor-
tantly, the association between TMAO levels and
eGFR was strong within our study cohort. How-
ever, we also observed that TMAO levels conferred
mortality risk prediction beyond traditional risk
factors, BNP, and eGFR, although the kidneys may
be physiologically impaired in eliminating TMAO
beyond eGFR.
The present study is the ﬁrst demonstration of
an association between elevated TMAO levels and
poor prognosis in patients with HF. Our ﬁndings
have several important implications that should be
discussed. First, by demonstrating the association
between TMAO and mortality risks in patients
with HF, our ﬁndings suggest that gut microbiota
composition and functional consequence may con-
tribute to disease progression during HF. With the
mechanistic link between TMAO and atherogenesis
in animal models (10,12), it is conceivable that pro-
gressive vascular remodeling and coronary athero-
genesis may occur in the setting of high TMAO
levels. Even in those with no known ischemic
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FIGURE 2 Relationship Between Plasma TMAO
Concentration and Mortality Risk Stratiﬁed According to
Baseline Characteristics
Forest plot of the hazard ratio (squares) of 5 year all cause
mortality risk comparing ﬁrst and fourth quartiles of fasting
plasma TMAO levels. Bars represent 95% CI. The wide CI in some
subgroups are in part due to their small sample sizes and event
rates. CAD coronary artery disease; eGFR estimated
glomerular ﬁltration rate; hsCRP high sensitivity C reactive
protein; other abbreviation as in Figure 1.


